Antibody-drug gold nanoantennas with Raman spectroscopic fingerprints for in vivo tumour theranostics

Joao Conde, Chenchen Bao, Daxiang Cui, Pedro Baptista, Furong Tian

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Inspired by the ability of SERS nanoantennas to provide an integrated platform to enhance disease targeting in vivo, we developed a highly sensitive probe for in vivo tumour recognition with the capacity to target specific cancer biomarkers such as epidermal growth factor receptors (EGFR) on human cancer cells and xenograft tumour models. Here, we used similar to 90 nm gold nanoparticles capped by a Raman reporter, encapsulated and entrapped by larger polymers and a FDA antibody-drug conjugate -Cetuximab (Erbitux (R)) - that specifically targets EGFR and turns off a main signalling cascade for cancer cells to proliferate and survive. These drug/ SERS gold nanoantennas present a high Raman signal both in cancer cells and inmice bearing xenograft tumours. Moreover, the Raman detection signal is accomplished simultaneously by extensive tumour growth inhibition in mice, making these gold nanoantennas ideal for cancer nanotheranostics, i.e. tumour detection and tumour cell inhibition at the same time. Published by Elsevier B.V.

Original languageEnglish
Pages (from-to)87-93
Number of pages7
JournalJournal Of Controlled Release
Volume183
DOIs
Publication statusPublished - 10 Jun 2014

Keywords

  • Nanotheranostics
  • Antibody-drug conjugates
  • Raman fingerprints
  • SERS
  • In vivo tumour targeting
  • SURFACE-PLASMON RESONANCE
  • METAL NANOPARTICLES
  • COLORECTAL-CANCER
  • ORAL-CANCER
  • SCATTERING
  • NANOCRYSTALS
  • LIGHT

Cite this